Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
about
Pathogenesis of minimal change nephrotic syndrome: an immunological conceptCell biology and genetics of minimal change diseaseExtracellular ATP induces albuminuria in pregnant ratsHemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes.A role for hemopexin in oligodendrocyte differentiation and myelin formation.Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.An alternative view of the proposed alternative activities of hemopexin.Nephrotic syndrome in children: from bench to treatmentPurified and recombinant hemopexin: protease activity and effect on neutrophil chemotaxisRecent advances in understanding and treating nephrotic syndrome.Plasma hemopexin as a potential regulator of vascular responsiveness to angiotensin II.Renal biopsy: use of biomarkers as a tool for the diagnosis of focal segmental glomerulosclerosis.Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.Biomarkers in IgA nephropathy.The glomerular permeability factors in idiopathic nephrotic syndrome.Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.Immunology of idiopathic nephrotic syndrome.Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.Genetics of childhood steroid-sensitive nephrotic syndrome.Minimal change disease and idiopathic FSGS: manifestations of the same disease.Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1.Nephrotic syndrome in infants and children: pathophysiology and management.Comprehensive and quantitative proteome profiling of the mouse liver and plasma.Plasma and urine proteomic profiles in childhood idiopathic nephrotic syndrome.Response to letter by Bakker et al.Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease.
P2860
Q26747387-8AF59603-80AA-4594-9F45-9DB751B0D2DEQ26752464-11C5DF27-D950-48E2-A312-37B0FE969C1CQ28571488-97FC595E-23B9-4028-8481-080CCCB7ACBCQ30484244-27BD26A0-010B-4130-89D5-A8CF4D19A3E5Q33919796-30E6FBF6-D821-4B69-AB48-C853C97A9B7FQ34491409-625D5EC5-1B2C-486F-BCC9-C6FB7AE4FD44Q34627609-CF8CD949-2C1F-4C36-A1E1-A6C1338CA7DEQ35185376-8A186983-C6FE-4A1F-A5E7-8663543EE74BQ37217041-448C2AA0-39EA-4FE8-B51E-8E235AB888A8Q37635783-E3C6B0AE-59C6-4F96-8FC8-7E462D504AB3Q38011051-3258602F-9B0B-4502-B2A9-39E9287A8FDFQ38203501-AF04FB38-8A91-4E81-BE90-BE60922E0C6FQ38270521-0A8D3F39-542D-4FFC-B070-E0B94DF49217Q38294669-B1C2F10D-3978-49E5-8DA9-ACC5FA9F3518Q38449629-F8AF2D67-BFF1-4912-BE7E-6BBFC81252D6Q38738516-D1CD6F7B-925F-4868-832B-4FA7BD44DB9EQ38815449-B466D4BE-F8A9-4136-AEB3-C7DA24FC6DD7Q38844709-7CEAD5E2-C895-4C19-A476-82EF8FFE9D3AQ38911915-ECB92988-8F49-4273-AD62-293097068DC7Q38982416-55908A1D-B8BF-4B27-8EB4-51F9C5C09674Q39189360-F9DD4CC6-E1D7-4F61-9B25-BD3998805E2DQ40039238-9C6EAA04-CB31-417F-8F24-70DE44C13DA3Q46760323-7B5EF64B-193F-4B6B-9439-571CB952A0EEQ47215250-A46A377C-58AE-4D8F-AF1D-C4C8D13E051CQ49844210-571FB05D-14DE-450B-AC70-8882463D2C60Q55251661-FADBA863-F966-4B81-912B-8AC9A9C35E64
P2860
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
@en
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
@nl
type
label
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
@en
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
@nl
prefLabel
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
@en
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
@nl
P2093
P1433
P1476
Altered activity of plasma hemopexin in patients with minimal change disease in relapse.
@en
P2093
Catharina M L van Dael
Jeroen Nauta
Joanna A E van Wijk
Jola J Kapojos
Leonie J W M Pierik
Theo Borghuis
Winston W Bakker
P2888
P304
P356
10.1007/S00467-005-1936-3
P577
2005-08-04T00:00:00Z